Premium
Simvastatin in vitiligo: an update with recent review of the literature
Author(s) -
Hasan Rashidul,
Agarwal Komal,
Podder Indrashis,
Misitzis Angelica,
Schwartz Robert A.,
Wollina Uwe,
Lotti Torello,
Grabbe Stephan,
Goldust Mohamad
Publication year - 2021
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.15330
Subject(s) - vitiligo , simvastatin , medicine , psoriasis , dermatology , quality of life (healthcare) , disease , medical literature , review article , intensive care medicine , pharmacology , pathology , nursing
Patients with vitiligo often seek medical attention, as it diminishes their quality of life resulting in significant morbidity. Several topical and systemic therapies are in vogue targeting the immunological aspect of this disease, but results are often unsatisfactory, and complete cure remains elusive. Recently, simvastatin, a 3‐hydroxy‐3‐methylyglutaryl‐coenzyme A (HMG‐CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. The proposed multimodal actions range from anti‐inflammatory, antioxidant, to immunomodulatory properties which may be of therapeutic benefit in vitiligo patients. The authors intend to evaluate the role of simvastatin as a novel therapeutic agent for vitiligo along with relevant review of literature.